Amgen Acquisition of Rodeo Therapeutics

March 30, 2021Client News

Gunderson Dettmer represented client Amgen Inc (NASDAQ:AMGN) in its acquisition of Rodeo Therapeutics. Amgen is one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

In the announcement of the transaction, Rodeo’s president and CEO Thong Q. Le said, "We are thrilled that Amgen recognizes the potential value and differentiated profile of our 15-PGDH inhibitor program.  With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and conditions, Amgen is ideally positioned to rapidly advance our program into the clinic."

The Gunderson deal team was led by John Olson and Kirt Shuldberg, and included Nick Feldman, Will Haynes, Steve Ray and Heather Aune.